Guideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemia

Study ID Citation

Wolfson JA, Grimes AC, Nuño MM, Ramakrishnan S, Dickens DS, Roth ME, Woods W, Adams KS, Alabi T, Beauchemin M, Levine JM, Scialla M, Boayue KB, Kerber CL, Ponce O, Vargas S, Chang GJ, Stock W, Hershman D, Curran E, Advani A, O’Dwyer K, Luger S, Liu JJ, Freyer DR, Sung L, Parsons SK. Guideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemia. JNCI Cancer Spectr. 2025 Apr 30;9(3):pkaf033. doi: 10.1093/jncics/pkaf033. PMID: 40238217; PMCID: PMC12121638.

Abstract

Individuals diagnosed with acute lymphoblastic leukemia (ALL) between adolescents and young adults aged 15-39 years face poor survival and unique challenges. We evaluated facility-level factors and guideline-concordant care among adolescents and young adults with ALL at National Cancer Institute Community Oncology Research Program (NCORP) practices.

Link To Publication opens in a new tab